Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 9.11 — trading above book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -11.5%
- Revenue growing at 32% annually
Glaukos Corporation (GKOS) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $6.0 billion . Key value metrics: P/B ratio 9.11, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Glaukos Corporation — Fundamental Analysis Summary
On financial health, GKOS shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -11.5% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.36.
StockPik's composite Value Score for GKOS is 32/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GKOS reports a high gross margin of 77.7% (sector average: 33.5%) and a negative operating margin of -18.3%.
GKOS shows revenue growing at 32% year-over-year, with earnings declining at 28%.